{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:24Z","timestamp":1791414144101,"version":"4.3.3"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,2]]},"abstract":"ABSTRACT<\/jats:title>\n \n Escherichia coli<\/jats:named-content>\n (328 isolates),\n Klebsiella pneumoniae<\/jats:named-content>\n (296),\n Klebsiella oxytoca<\/jats:named-content>\n (44), and\n Proteus mirabilis<\/jats:named-content>\n (33) isolates collected during 2012 from the nine U.S. census regions and displaying extended-spectrum-\u03b2-lactamase (ESBL) phenotypes were evaluated for the presence of \u03b2-lactamase genes, and antimicrobial susceptibility profiles were analyzed. The highest ESBL rates were noted for\n K. pneumoniae<\/jats:named-content>\n (16.0%, versus 4.8 to 11.9% for the other species) and in the Mid-Atlantic and West South Central census regions. CTX-M group 1 (including CTX-M-15) was detected in 303 strains and was widespread throughout the United States but was more prevalent in the West South Central, Mid-Atlantic, and East North Central regions. KPC producers (118 strains [112\n K. pneumoniae<\/jats:named-content>\n strains]) were detected in all regions and were most frequent in the Mid-Atlantic region (58 strains). Thirteen KPC producers also carried\n bla<\/jats:italic>\n CTX-M<\/jats:sub>\n . SHV genes encoding ESBL activity were detected among 176 isolates. Other \u03b2-lactamase genes observed were CTX-M group 9 (72 isolates), FOX (10), TEM ESBL (9), DHA (7), CTX-M group 2 (3), NDM-1 (2 [Colorado]), and CTX-M groups 8 and 25 (1). Additionally, 62.9% of isolates carried \u22652 \u03b2-lactamase genes. KPC producers were highly resistant to multiple agents, but ceftazidime-avibactam (MIC\n 50\/90<\/jats:sub>\n , 0.5\/2 \u03bcg\/ml) and tigecycline (MIC\n 50\/90<\/jats:sub>\n , 0.5\/1 \u03bcg\/ml) were the most active agents tested. Overall, meropenem (MIC\n 50<\/jats:sub>\n , \u22640.06 \u03bcg\/ml), ceftazidime-avibactam (MIC\n 50<\/jats:sub>\n , 0.12 to 0.5 \u03bcg\/ml), and tigecycline (MIC\n 50<\/jats:sub>\n , 0.12 to 2 \u03bcg\/ml) were the most active antimicrobials when tested against this collection. NDM-1 producers were resistant to all \u03b2-lactams tested. The diversity and increasing prevalence of \u03b2-lactamase-producing\n Enterobacteriaceae<\/jats:named-content>\n have been documented, and ceftazidime-avibactam was very active against the vast majority of \u03b2-lactamase-producing strains isolated from U.S. hospitals.\n <\/jats:p>","DOI":"10.1128\/aac.01896-13","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T04:59:32Z","timestamp":1384837172000},"page":"833-838","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":170,"title":["Contemporary Diversity of \u03b2-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent \u03b2-Lactamase Groups"],"prefix":"10.1128","volume":"58","author":[{"given":"Mariana","family":"Castanheira","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Farrell","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Krause","sequence":"additional","affiliation":[{"name":"Cerexa, Inc., Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01848.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00576-07"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2008.0827"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq393"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir202"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks063"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2012.0238"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis562"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-12"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir401"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00234-12"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp197"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00817-12"},{"key":"e_1_3_2_15_2","volume-title":"M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_16_2","volume-title":"M100-S23Performance standards for antimicrobial susceptibility testing: 23rd informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_17_2","unstructured":"EUCAST. 2013. Breakpoint tables for interpretation of MICs and zone diameters version 3.0 January 2013. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 2 January 2013."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/653932"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1151-1161.2001"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr081"},{"key":"e_1_3_2_21_2","first-page":"108","article-title":"Notes from the field: hospital outbreak of carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase\u2014Denver, Colorado, 2012","volume":"62","author":"Pisney L","year":"2013","unstructured":"PisneyLBarronMJanelleSBambergWMacCannellDKallenAGouldCLimbagoBEpsonEWendtJ. 2013. Notes from the field: hospital outbreak of carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase\u2014Denver, Colorado, 2012. MMWR Morb. Mortal. Wkly. Rep. 62:108. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6206a5.htm.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_22_2","volume-title":"Tygacil package insert","author":"Pfizer, Inc","year":"2012","unstructured":"Pfizer, Inc. 2012. Tygacil package insert. Pfizer, Inc, New York, NY. http:\/\/www.tygacil.com. Accessed 2 January 2013."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01896-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01896-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:35:36Z","timestamp":1645482936000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01896-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1128\/AAC.01896-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01896-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"2013-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}